Eli Lilly: positive data in sleep apnea
Tirzepatide achieved a mean AHI reduction of up to 63% (approximately 30 fewer events per hour), meeting all key primary and secondary endpoints in two phase III clinical trials.
More broadly, the product significantly improved symptoms in people with moderate to severe obstructive sleep apnea and obesity with and without positive airway pressure treatment.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction